Therapies targeting the immune system immuno-oncology candidates, in particular are all the rage of late, but Bioniz Therapeutics Inc. is taking a different tack in its scientific approach to the immuno-inflammatory space. This week, the company closed a $13 million series A co-led by Takeda Ventures Inc. and David Pyott, former CEO of Allergan Inc., with participation from Joe Kiani, founder, chairman and CEO of med-tech company Masimo Corp., and Cota Capital.
Pyott was named chairman of the board at the Irvine, Calif.-based company, joined by Ilan Zipkin, senior investment director of Takeda Ventures, and Kiani.
According to SEC filings, the company previously raised approximately $4.9 million in several small rounds between 2013 and year-end 2015.
The company's lead compound,